Skip to main content
Clinical Trials/NCT05665985
NCT05665985
Completed
Phase 1

Effect Of Moringa Leaf Extract On Disease Activity In Rheumatoid Arthritis Patients

Universitas Sebelas Maret1 site in 1 country30 target enrollmentStarted: May 1, 2020Last updated:

Overview

Phase
Phase 1
Status
Completed
Enrollment
30
Locations
1
Primary Endpoint
DAS-28 ESR

Overview

Brief Summary

Intervention therapy study of moringa oliefera extract on the degree of activity of rheumatoid arthritis patients. The research subjects were patients with rheumatoid arthritis-intervention with moringa oliefera for 30 days.

Detailed Description

Rheumatoid arthritis is a progressive autoimmune disease. Delay in therapy and delay in remission will result in disability. This study is a randomized clinical trial using a new drug for rheumatoid arthritis, moringa oliefera. The choice of moringa oliefera was due to the ability of moringa oliefera in anti-inflammatory and immunosuppressant terms. This drug has also been proven in experimental studies on rheumatoid arthritis animals. This study with 30 research samples divided into two groups, containing 15 samples each for the treatment group and 15 for the control group. The treatment group was given Moringa oleifera extract of 40.50 mg/KGBW/day, while the control group was given a placebo for 30 days.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Masking Description

The capsule form between the drug and the placebo was the same, there was no drug name label on the drug packaging, and only a number was given on the drug packaging.

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of RA criteria according to the ACR / EULAR 2010
  • Visual analog score of more than three.

Exclusion Criteria

  • Pregnancy
  • Using Methylprednisolone\> 8 mg per day
  • Using NSAIDs
  • Chronic Kidney Disease
  • Diabetes Mellitus
  • Heart Failure
  • Lever disease

Arms & Interventions

Moringa Oliefera

Experimental

Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.

Intervention: Moringa Oleifera (Drug)

Placebo

Placebo Comparator

Capsules similar to moringa oliefera, which contain powder, have no pharmacological effect.

Intervention: Moringa Oleifera (Drug)

Outcomes

Primary Outcomes

DAS-28 ESR

Time Frame: pre and post intervention (30 day)

The change of Disease activity score in Rheumatoid arthritis patients

DAS-28 CRP

Time Frame: pre and post intervention (30 day)

The change of Disease activity score in Rheumatoid arthritis patients

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Nurhasan Agung Prabowo

Head of Hospital Research Unit

Universitas Sebelas Maret

Study Sites (1)

Loading locations...

Similar Trials